LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Purchased by Federated Hermes Inc.

Federated Hermes Inc. grew its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 38,121.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 38,986 shares of the medical instruments supplier's stock after acquiring an additional 38,884 shares during the quarter. Federated Hermes Inc. owned about 0.17% of LeMaitre Vascular worth $3,592,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of LMAT. Allspring Global Investments Holdings LLC increased its position in LeMaitre Vascular by 48.2% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 13,321 shares of the medical instruments supplier's stock worth $1,227,000 after purchasing an additional 4,330 shares in the last quarter. Barclays PLC increased its position in shares of LeMaitre Vascular by 394.5% in the third quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier's stock worth $3,396,000 after acquiring an additional 29,180 shares in the last quarter. Compass Planning Associates Inc purchased a new position in shares of LeMaitre Vascular in the 4th quarter valued at $567,000. Teacher Retirement System of Texas raised its stake in shares of LeMaitre Vascular by 31.8% in the 4th quarter. Teacher Retirement System of Texas now owns 101,851 shares of the medical instruments supplier's stock valued at $9,385,000 after acquiring an additional 24,586 shares during the period. Finally, Congress Asset Management Co. lifted its holdings in shares of LeMaitre Vascular by 1.8% during the 4th quarter. Congress Asset Management Co. now owns 722,325 shares of the medical instruments supplier's stock valued at $66,555,000 after acquiring an additional 13,009 shares in the last quarter. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,009 shares of LeMaitre Vascular stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total value of $164,979.08. Following the completion of the transaction, the insider now directly owns 5,564 shares in the company, valued at $456,915.68. The trade was a 26.53 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 10.79% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

LMAT has been the topic of several research reports. Oppenheimer lowered LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Lake Street Capital boosted their price target on LeMaitre Vascular from $105.00 to $110.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. Wells Fargo & Company started coverage on shares of LeMaitre Vascular in a research report on Thursday, February 13th. They issued an "equal weight" rating and a $95.00 price objective for the company. Finally, Barrington Research cut shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Five research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $95.25.

LeMaitre Vascular Price Performance

LMAT traded up $1.61 during trading on Friday, hitting $86.28. The company had a trading volume of 184,020 shares, compared to its average volume of 160,516. LeMaitre Vascular, Inc. has a 1-year low of $62.39 and a 1-year high of $109.58. The company has a market cap of $1.95 billion, a PE ratio of 47.15, a P/E/G ratio of 2.22 and a beta of 0.89. The business has a 50-day moving average of $88.07 and a 200-day moving average of $93.51.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 EPS for the quarter, hitting the consensus estimate of $0.49. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The business had revenue of $55.81 million for the quarter, compared to analysts' expectations of $55.99 million. Research analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 27th. Shareholders of record on Thursday, March 13th were issued a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 0.93%. The ex-dividend date was Thursday, March 13th. This is an increase from LeMaitre Vascular's previous quarterly dividend of $0.16. LeMaitre Vascular's payout ratio is currently 41.24%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.